Michael Brady Lynch to Lecture on Handling the Pradaxa Claim
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. I am proud to announce that I have been asked to lecture to my fellow attorneys at the upcoming American Association for Justice’s (AAJ) seminar “Handling the Pradaxa Claim” on April 11 in Baltimore, MD. I will educate my colleagues on
Read MoreNJ Supreme Court Decision Strengthens Consumer Rights
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. Finally, some good news to report on the judicial front. Kendall v. Hoffman-LaRoche is an excellent decision from the NJ Supreme Court on the statute of limitations and discovery rule in pharma cases, declining to adopt any warnings adequate as a matter
Read MoreTransvaginal Mesh Cases Consolidated in West Virginia
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. I am not always in favor of the consolidation of mass torts cases into a federal MDL, but in the case of transvaginal mesh cases, I think the recent order consolidating the litigation involving several of the major transvaginal mesh defendants
Read MoreMichael Brady Lynch New Trial Lawyer with AAJ
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. I am proud to call myself a trial lawyer. To me, being a trial lawyer carries with it the responsibility and obligation to serve as a consumer advocate and stand up for the rights of Americans injured by big pharmaceutical companies.
Read MoreInjury Spotlight: Pradaxa Bleeding Dangers
Update: Pradaxa tied for first place as the drug most linked to adverse event reports filed with the FDA in 2011, showing that it is among the highest risk of all drug treatments, reported QuarterWatch, a non-profit drug monitoring organization. The FDA received reports of 3,781 serious, harmful events in 2011, as well as 542 deaths in the U.S. alone. Pradaxa surpassed all other drugs for negative reports involving hemorrhage, acute renal (kidney) failure and stroke. The growing crisis involving the blood thinner Pradaxa can be described in one word – scary…
Read MoreLitigation Explosion Looming Over Wright Hip Implant Failures
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. In my over 15 years of experience litigating medical device cases, I have seen any number of defectively designed hip implants. For months I have been watching with great interest the growing reports of complications and failures with the Wright Profemur
Read MorePfizer Requests MDL Consolidation of Zoloft Lawsuits
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. It looks like we will likely soon see a Zoloft MDL. It appears that Pfizer has had enough of the possibility of lawsuits springing up in various jurisdictions across the country alleging birth defects caused by the drug Zoloft. On January
Read MoreCrestor, Statins and the Risk of Diabetes and Cardiomyopathy
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. As my regular readers are aware, I am the founder and Chair of the American Association for Justice’s (AAJ) Crestor Litigation Group, a collection of pharmaceutical mass tort attorneys dedicated to advancing litigation involving the harmful effects of treatment with the
Read MorePropecia Lawsuit Filed In Los Angeles
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. As my regular readers are aware, I have been lecturing fellow attorneys on the association between Propecia and sexual dysfunction for well over two years. Now, cases are being filed in Los Angeles in California state court against Merck, the maker
Read More
Lots of Movement on the Actos Bladder Cancer Litigation Front
Some very interesting developments in the Actos bladder cancer litigation have occurred over the last few days. This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. Happy New Year to everyone! About the MDL First, the new Actos bladder cancer MDL has been formed. Christened MDL No. 2299, Actos bladder cancer
Read More